Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other dis…
$3.46+10.19%
报价 2026-11-09
市值
$227.9M
EV
$352.3M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -46.9%
$2.08$6.51
筛选结果
pipeline · 2026-11-09Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| GALTGalectin Therapeutics Inc. | $227.9M | +10.2% | +395.0% | 0% | – | – | – | |
| LBRXLB Pharmaceuticals Inc Common Stock | $1.46B | +7.4% | – | 0% | – | – | – | |
| DRTSAlpha Tau Medical Ltd. | $1.3B | +2.8% | – | 0% | – | – | – | |
| AURAAura Biosciences, Inc. | $794.4M | +16.8% | +2.7% | 0% | – | – | – | |
| DSGNDesign Therapeutics, Inc. | $675.9M | +5.8% | +141.9% | 0% | – | – | – | |
| DMACDiaMedica Therapeutics Inc. | $520.4M | +3.1% | +10700.0% | 0% | – | – | – | |
| ALTAltimmune, Inc. | $412.4M | +1.9% | -100.0% | -36,387.8% | – | – | – | |
| RCKTRocket Pharmaceuticals, Inc. | $277.7M | +6.1% | +360.0% | 0% | – | – | – | |
| QSIQuantum-Si incorporated | $272.6M | +3.0% | -64.3% | 34.9% | – | – | – | |
| 同行中位数 | – | – | +72.3% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。